At the six-week mark of its fifty-four-week study, Pfizer released data for its biosimilar, Inflectra as a treatment for Crohn’s disease. Previously, Inflectra was approved to treat moderate to severe Crohn’s disease but did not have Crohn’s-specific data. With its new data, the biosimilar may be en route to compete with Johnson & Johnson’s Remicade on a global scale. Though the market success of biosimilar drugs still remains reliant upon physician prescription, Pfizer is confident in moving forward with Crohn’s-focused marketing. Read the full article here.
